Ardelyx Faces Access Hurdles, Adjusts Guidance | Business and Finance News

Ardelyx reports record-breaking Q2 revenue of $180M, up 31% YoY, driven by strong demand for IBSRELA — but missed internal targets due to payer access hurdles. Despite revised IBSRELA guidance to $350M–$370M and dropping litigation against CMS, the company’s four-pronged strategy to expand reimbursement, pharmacy networks, provider engagement, and DTC campaigns aims to unlock growth. XPHOZAH shows resilience with 27% YoY growth, and its guidance remains intact at $110M–$120M. While IBSRELA’s $1B goal may shift, Ardelyx is cutting XPHOZAH’s guidance amid market uncertainty, staying disciplined on spending while targeting profitability by 2027. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/ea42f34aaffbc9c2